Synageva BioPharma moves, names new CEO

By Mass High Tech Staff

Sanofi/Genzyme MS drug meets mostly positive data results [July 11, 2011]

MLSC’s Windham-Bannister sees agency driving growth [April 1, 2009]

MHT survey: Largest tech companies shed 10K jobs since 2008 [March 26, 2009]

Surgenor joins NeuroMetrix board [March 18, 2009]

Biopharmaceuticals firm Synageva BioPharma Corp. has opened new headquarters in Waltham and named Sanj K. Patel as president and CEO of the company.

Synageva, originally founded in the Atlanta area as Avigenics, makes biopharmaceutical products for commercialization relating to oncology, genetic diseases and autoimmune diseases. The company continues to use its Atlanta-area office for research and production.

Patel joins Synageva following nine years at Genzyme Corp., where he most recently served as head of U.S. sales, marketing and commercial operations for Genzyme Therapeutics. In addition, he held clinical research and commercial development positions with Burroughs, Wellcome, Hoescht Marion Rousel and Fujisawa Pharmaceutical Co. Ltd.

Patel earned his Ph.D. in clinical pharmacology from King’s College and the Wellcome Foundation and his bachelo’s degree in pure and applied biotechnology from South Bank University in London.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.